SEC Form 4 · accession 0001209191-15-075364
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil James Clendeninn
Officer — SVP & Chief Medical Officer
Period of report
Oct 12, 2015
Accepted (ET)
Oct 13, 2015 · 9:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818033
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $28.30 | Oct 12, 2015 | A | 100,000 | A | — | Oct 12, 2025 | Common Stock | 100,000 | 100,000 | D |
| Stock Option (Right to Buy)F2 | $28.30 | Oct 12, 2015 | A | 50,000 | A | — | Oct 12, 2025 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Options shall vest and become exercisable with respect to 25,000 shares on the first anniversary of his first day of employment (the "Grant Date"), followed by 75,000 shares vesting ratably each month over the subsequent three years, such that 100,000 options will be fully vested on the four year anniversary of the Grant Date.
- F2Option shall vest and become exercisable in full upon approval of SUSTOL (granisetron) Injection, extended release by the U.S. Food and Drug Administration.